U.K. watchdogs reject Vertex's CF med Orkambi, citing $147K annual cost

Vertex Pharmaceuticals ($VRTX) is facing a roadblock in the U.K. for its new, pricey cystic fibrosis treatment Orkambi. The country's National Institute for Health and Care Excellence (NICE) recommended against funding the drug, saying that it did not demonstrate enough benefits to patients to justify its high cost. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.